关键信息
-
基因名
ADAM12
- 应用
-
别名
ADAM12；MLTN；Disintegrin and metalloProteinase domain-containing Protein 12
-
种属
Mouse
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q61824
-
表达区间
206-706aa
-
氨基酸序列
ETLKMTKYVELVIVADNREFQRQGKDLEKVKQRLIEIANHVDKFYRPLNI RIVLVGVEVWNDIDKCSISQDPFTSLHEFLDWRKIKLLPRKSHDNAQLIS GVYFQGTTIGMAPIMSMCTAEQSGGVVMDHSDSPLGAAVTLAHELGHNFG MNHDTLERGCSCRMAAEKGGCIMNPSTGFPFPMVFSSCSRKDLEASLEKG MGMCLFNLPEVKQAFGGRKCGNGYVEEGEECDCGEPEECTNRCCNATTCT LKPDAVCAHGQCCEDCQLKPPGTACRGSSNSCDLPEFCTGTAPHCPANVY LHDGHPCQGVDGYCYNGICQTHEQQCVTLWGPGAKPAPGICFERVNSAGD PYGNCGKDSKSAFAKCELRDAKCGKIQCQGGASRPVIGTNAVSIETNIPQ QEGGRILCRGTHVYLGDDMPDPGLVLAGTKCAEGKICLNRRCQNISVFGV HKCAMQCHGRGVCNNRKNCHCEAHWAPPFCDKFGFGGSTDSGPIRQADNQ G
-
分子量
58 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
ADAM12 (A Disintegrin and Metalloproteinase 12) is a member of the ADAM family, which is characterized by its disintegrin and metalloproteinase domains. It plays a crucial role in various biological processes, including cell adhesion, motility, and proteolytic cleavage of substrates, which are essential for development and tissue remodeling. Research has indicated that ADAM12 is involved in pathological conditions such as cancer progression, inflammation, and cardiovascular diseases. Its expression levels can serve as potential biomarkers for certain cancers, making it an attractive target for therapeutic intervention. The recombinant expression of ADAM12 has generated significant interest, as it enables the study of its functional domains and interactions with other proteins. By producing ADAM12 in a recombinant form, researchers can investigate its enzymatic activity, inhibition mechanisms, and interactions with various substrates, providing insights into its role in disease processes. Furthermore, understanding ADAM12's structure-function relationship could lead to the development of specific inhibitors that may have therapeutic implications in cancer therapy and other diseases associated with dysregulated ADAM12 activity. Thus, the investigation of recombinant ADAM12 is not only vital for elucidating its biological functions but also for exploring its potential as a therapeutic target.
